Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
Active surveillance vs ablation for small kidney tumors: what works?
This systematic review and meta-analysis evaluates active surveillance (AS) versus ablative therapy (AT) for patients with small renal masse…
For small kidney tumors, ablation may boost survival, but cancer-specific death risk is similarly low with either approach.
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
Small kidney tumors may not need surgery right away
This prospective multi-institutional study evaluated active surveillance in patients aged over 50 years with asymptomatic, unilateral small …
Many small kidney tumors stay harmless for years, meaning patients might avoid surgery and its risks without putting their health in danger.
Case report and literature review on mosaic DICER1 mutations and disease stability in a 6-month-old boy
One Baby, Five Tumors, One Tiny Gene Change
This case report and literature review describes a 6-month-old boy with mosaic DICER1 RNase IIIb hotspot mutation and multiple tumors.
A 6-month-old boy developed five different tumors linked to one small gene change, showing how one mutation can drive multiple childhood can…
Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
Old cancer drugs failed, but one new drug saves high-risk kidney patients today
This narrative review evaluates adjuvant therapies for renal cell carcinoma, including cytokine-based immunotherapy, VEGF-targeted agents, a…
Doctors finally have a powerful new tool to stop kidney cancer from coming back after surgery, but it only works for specific patients.
Open-sourcing data and annotations for renal cell carcinoma yielded 142 annotated CT scans from 101 patients
Open-source CT scans aim to boost kidney cancer AI research
This cohort study involved 101 patients with renal cell carcinoma (RCC) and analyzed 142 annotated CT scans.
Researchers release 142 annotated CT scans from 101 kidney cancer patients to accelerate AI development.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Office-based holmium-YAG TULA shows feasibility and safety for recurrent NMIBC in a high-risk cohort
Laser Treatment for Bladder Cancer Now Done in Office
This retrospective cohort study evaluated 53 patients undergoing their first office-based transurethral laser ablation (TULA) for recurrent …
Men with small, recurring bladder tumors can now get laser treatment in an office instead of surgery, avoiding hospital stays and general an…
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
Low Drug Levels Mean Worse Outcomes
This randomized phase 2 trial evaluated nivolumab and ipilimumab trough plasma concentrations in 110 patients with metastatic clear cell ren…
Low levels of a common kidney cancer drug are linked to worse survival outcomes when used with another powerful medicine.